title: [Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin].
abstract: An effect of a new nootropic drug noopept on the dynamics of main EEG rhythms and narrow-band spectral EEG characteristics in patients with cerebral asthenic and cognitive disturbances caused by traumas or vascular brain diseases has been studied. Noopept caused the EEG changes characteristic of the action of nootropics: the increase of alpha- and beta-rhythms power and reduction of delta-rhythms power. The reaction of alpha-rhythm was provided mostly by the dynamics of its low and medium frequencies (6,7-10,2 Hz), the changes of beta-rhythm were augmented in frontal and attenuated in occipital areas. The analysis of frequency and spatial structure of EEG changes reveals that noopept exerts a nonspecific activation and anxyolytic effect. The differences in EEG changes depending on the brain pathology were found. The EEG indices of nootropic effect of the drug were most obvious in cerebral vascular diseases. The EEG changes in posttraumatic brain lesion were less typical.
authors.forename: V K
authors.initials: VK
authors.lastname: Bochkarev
authors.forename: E S
authors.initials: ES
authors.lastname: Teleshova
authors.forename: S A
authors.initials: SA
authors.lastname: Siuniakov
authors.forename: D V
authors.initials: DV
authors.lastname: Davydova
authors.forename: G G
authors.initials: GG
authors.lastname: Neznamov
mesh_terms: D000328:Adult; D001921:Brain / Q000098:blood supply* / Q000503:physiopathology*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D004151:Dipeptides / Q000494:pharmacology* / Q000627:therapeutic use*; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013313:Stress Disorders, Post-Traumatic / Q000150:complications* / Q000503:physiopathology*
chemical_list: D004151:Dipeptides; D006442:Glycated Hemoglobin; D018697:Nootropic Agents; C103871:ethyl phenylacetyl-Pro-Gly